This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Infliximab dose escalation not uncommon during first year in RA. Pharmacoecon. Outcomes News 494, 4 (2006). https://doi.org/10.2165/00151234-200604940-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200604940-00008